<?xml version='1.0' encoding='utf-8'?>
<document id="29678521"><sentence text="Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions."><entity charOffset="73-81" id="DDI-PubMed.29678521.s1.e0" text="aldehyde" /></sentence><sentence text="As aldehyde oxidase (AOX) plays an emerging role in drug metabolism, understanding its significance for drug-drug interactions (DDI) is important"><entity charOffset="3-11" id="DDI-PubMed.29678521.s2.e0" text="aldehyde" /></sentence><sentence text=" Therefore, we tested 10 compounds for species-specific and substrate-dependent differences in the inhibitory effect of AOX activity using genetically engineered HEK293 cells over-expressing human AOX1, mouse AOX1 or mouse AOX3" /><sentence text=" The IC50 values of 10 potential inhibitors of the three AOX enzymes were determined using phthalazine and O6-benzylguanine as substrates"><entity charOffset="91-102" id="DDI-PubMed.29678521.s4.e0" text="phthalazine" /><entity charOffset="107-123" id="DDI-PubMed.29678521.s4.e1" text="O6-benzylguanine" /><pair ddi="false" e1="DDI-PubMed.29678521.s4.e0" e2="DDI-PubMed.29678521.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29678521.s4.e0" e2="DDI-PubMed.29678521.s4.e1" /></sentence><sentence text=" 17β-Estradiol, menadione, norharmane and raloxifene exhibited marked differences in inhibitory effects between the human and mouse AOX isoforms when the phthalazine substrate was used"><entity charOffset="1-14" id="DDI-PubMed.29678521.s5.e0" text="17β-Estradiol" /><entity charOffset="16-25" id="DDI-PubMed.29678521.s5.e1" text="menadione" /><entity charOffset="27-37" id="DDI-PubMed.29678521.s5.e2" text="norharmane" /><entity charOffset="42-52" id="DDI-PubMed.29678521.s5.e3" text="raloxifene" /><entity charOffset="154-165" id="DDI-PubMed.29678521.s5.e4" text="phthalazine" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e0" e2="DDI-PubMed.29678521.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e0" e2="DDI-PubMed.29678521.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e0" e2="DDI-PubMed.29678521.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e0" e2="DDI-PubMed.29678521.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e0" e2="DDI-PubMed.29678521.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e1" e2="DDI-PubMed.29678521.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e1" e2="DDI-PubMed.29678521.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e1" e2="DDI-PubMed.29678521.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e1" e2="DDI-PubMed.29678521.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e2" e2="DDI-PubMed.29678521.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e2" e2="DDI-PubMed.29678521.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e2" e2="DDI-PubMed.29678521.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e3" e2="DDI-PubMed.29678521.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29678521.s5.e3" e2="DDI-PubMed.29678521.s5.e4" /></sentence><sentence text=" Some of the compounds tested exhibited substrate-dependent differences in their inhibitory effects" /><sentence text=" Docking simulations with human AOX1 and mouse AOX3 were conducted for six representative inhibitors" /><sentence text=" The rank order of the minimum binding energy reflected the order of the corresponding IC50 values" /><sentence text=" We also evaluated the potential DDI between an AOX substrate (O6-benzylguanine) and an inhibitor (hydralazine) using chimeric mice with humanized livers"><entity charOffset="63-79" id="DDI-PubMed.29678521.s9.e0" text="O6-benzylguanine" /><entity charOffset="99-110" id="DDI-PubMed.29678521.s9.e1" text="hydralazine" /><pair ddi="false" e1="DDI-PubMed.29678521.s9.e0" e2="DDI-PubMed.29678521.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29678521.s9.e0" e2="DDI-PubMed.29678521.s9.e1" /></sentence><sentence text=" Pretreatment of hydralazine increased the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC0-24) of O6-benzylguanine compared to single administration"><entity charOffset="17-28" id="DDI-PubMed.29678521.s10.e0" text="hydralazine" /><entity charOffset="147-163" id="DDI-PubMed.29678521.s10.e1" text="O6-benzylguanine" /><pair ddi="false" e1="DDI-PubMed.29678521.s10.e0" e2="DDI-PubMed.29678521.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29678521.s10.e0" e2="DDI-PubMed.29678521.s10.e1" /></sentence><sentence text=" Our in vitro data indicate species-specific and substrate-dependent differences in the inhibitory effects on AOX activity" /><sentence text=" Our in vivo data demonstrate the existence of a DDI which may be of relevance in the clinical context" /><sentence text="" /></document>